Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.00 (0.00%)
Bid:
1.55
Ask:
1.85
Spread: 0.30 (19.355%)
Market Cap: £264.88k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Operational update

10 Dec 2020 07:00

RNS Number : 1375I
Iconic Labs PLC
10 December 2020
 

 

 

 

Iconic Labs Plc ("Iconic Labs" or the "Company")

 

Operational Update

 

 

Iconic Labs Plc (LSE:ICON), a multidivisional new media and technology business, today provides the following operational update covering activity during the second half of 2020.

The second half of this year saw material positive progress in the business activity of the Company. In particular, monthly contracted revenues now exceed £135,000 per month (more than £1.5 million on an annualised basis, up from £0.1m for the entirety of 2020). In parallel, legacy revenues have now largely been dealt with and running costs for the Company are running at a level similar to or less than revenues received.

The key transformative event was the acquisition by Greencastle Acquisition Limited ("Greencastle Capital") of the JOE and HER media group and the subsequent entering into of a management service contract ("MSC") with the Company. The management fee payable for the provision of all management services to Greencastle Capital under a single combined MSC with the Company is now £125,000 a month, which over the course of a 12 month contract alone exceeds the amount of income that Iconic had generated in the financial year ended 30 June 2020.

The management team have worked very hard with the JOE team to run the business more efficiently, and JOE UK is now operationally profitable less than 4 months after the commencement of the provision of the management services under the MSC. This is particularly important, as in addition to the £125,000 a month fee payable to the Company under the MSC, the Company is also entitled to a 25% profit share of JOE Media. Since the management team have been providing their services under the MSC a number of high value contracts have been won on a regular basis, including most recently a series of recent advertising and branded content partnerships with revenues totalling more than £750,000. JOE Media is a business that has historically achieved more than £10 million in annual revenue and has seen previous revenue growth rates of over 100% a year. We are confident that with the experience and expertise that the management team provides under the MSC, JOE Media can increase its profits which in turn can become a significant source of revenue to the Company in the future.

The directors believe there remains a number of further acquisition and partnership opportunities in the digital media and advertising sector and through which it can establish partnerships with brands and businesses. It is the Company's belief that there are many potential partners that can benefit from the experience and contacts of the Iconic Labs management team, specifically dramatically scaling monetisation efforts across previously under-monetised websites and digital brands via both programmatic advertising and branded content contracts. The performance of JOE Media provides clear verification of the ability of the management team of the Company to do so.

In addition to the success of the contract wins achieved by JOE Media, as a result of the management services provided by the management team, there has also been a focus on operational efficiencies, and in doing so under the MSC, the management team have made JOE Media a more structured and streamlined platform and business. This is not only about reducing unnecessary costs but also structuring the business so it is optimised operationally and can benefit from both economies of scale and accessing greater levels of revenues. Size and scale are often limiting factors in a digital media company's revenue prospects and that is why JOE Media was such a transformational partnership, as this allowed the business to achieve enough of both so as to achieve a different level of revenue growth. The result is that the JOE Media business is now well positioned to achieve further synergies by working with other owned and operated platforms.

The recently announced entering into of a further MSC in respect of the Lovin Media business following its acquisition by Greencastle Capital is an example of this model already being put into action. The JOE Media and Lovin Media businesses are now being run as one and together form the largest independent digital media company in Ireland. This will help create both revenue and cost synergies which the Company believes should increase revenues and profitability across all entities. As a result of this the fee that Iconic Labs receive on a monthly basis has been to £125,000 (£1.5m annually), together with the potential of receiving 25% of the profits. As previously mentioned, the MSC for both businesses is now being undertaken under a single combined MSC with Greencastle Capital.

 

In addition, the other owned and operated business, GSN and The London Economic (TLE), are also benefiting from the centralized systems and resources we have created. TLE provides regular revenue to Iconic Labs under a separate MSC. Importantly, TLE is now profitable. There are also exciting opportunities for the JOE Media commercial team to upsell TLE distribution and content onto JOE Media contracts. This should provide an opportunity to substantially increase revenues from branded content campaigns. Similarly GSN will not only benefit in all areas commercially but will also be able to share resources such as production of content. This should not only contribute to revenues but also greatly enhance the capital value of the GSN brand.

 

Finally, one of the most important aims that the board of directors had for this year was to build the underlying business to a level where it could attract conventional capital funding, and in so doing move away from the convertible loan note facility funding model that had been inherited from the old WideCells business, and as previously announced, the Company has been successful in doing so. With the previous financing facility having been terminated, and a recent equity raise being successfully completed, the Company is well placed to grow the share price alongside the growth of the Company. There are ongoing discussions with the previous provider of the convertible loan note facility as to the settlement of the outstanding amounts due which are to be resolved. Negotiations on this are not straight forward, but the Company is determined to negotiate with the best interests of its members and other stakeholders in mind and ensure that any final settlement is one which can be fully justified to them.

 

 

John Quinlan, CEO of Iconic Labs, said: "We are delighted that the hard work of the team, and the patience of the shareholders is beginning to be rewarded by substantial positive progress in the Iconic Labs business. Increasing revenues to more than £1.5m on annualised basis shows that the model and playbook we have been working to is beginning to show the benefits of a substantial amount of work over the previous 18 months."

 

 

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

**ENDS**

For further information, please visit the Company's website www.iconiclabs.co.uk or contact:

Damon Heath

Shard Capital Partners LLP

Tel: +44 (0) 20 7186 9950

Iconic Labs ir@iconiclabs.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFSDFTLAIII
Date   Source Headline
30th Oct 20184:25 pmRNSNotice of AGM
30th Oct 20182:05 pmRNSSecond Price Monitoring Extn
30th Oct 20182:00 pmRNSPrice Monitoring Extension
30th Oct 20187:00 amRNSWideacademy Restructuring
29th Oct 20184:33 pmRNSHolding(s) in Company
23rd Oct 20188:27 amRNSConversion of Bond
22nd Oct 20183:27 pmRNSConversion of bonds
22nd Oct 20187:00 amRNSSmart Cells Deal
19th Oct 20189:20 amRNSHolding(s) in Company
18th Oct 201812:47 pmRNSBoard Restructuring
17th Oct 20184:48 pmRNSHolding(s) in Company
1st Oct 201811:00 amRNSPrice Monitoring Extension
28th Sep 20183:30 pmRNSHolding(s) in Company
27th Sep 20184:40 pmRNSSecond Price Monitoring Extn
27th Sep 20184:35 pmRNSPrice Monitoring Extension
27th Sep 201810:40 amRNSNotification of transactions of Directors
27th Sep 20187:10 amRNSInterim Results
27th Sep 20187:00 amRNSFinancing Agreement
30th Jul 20187:00 amRNSCellPlan Launch in Spain
9th Jul 20187:01 amRNSBoard Changes
9th Jul 20187:00 amRNSHolding(s) in Company
29th Jun 20183:00 pmRNSResult of AGM
28th Jun 201810:30 amRNSResult of General Meeting
15th Jun 20187:00 amRNSAlign Research Initiation of Coverage
12th Jun 20186:25 pmRNSProspectus and Notice of General Meeting
11th Jun 20189:00 amRNSLive Market Bookbuild Closes
11th Jun 20187:30 amRNSRestoration Widecells Group Plc
11th Jun 20187:00 amRNSUpdate Regarding Placing and Financial Position
6th Jun 20183:00 pmRNSNotice of AGM
5th Jun 20187:00 amRNSAudited Preliminary Results
21st May 20187:00 amRNSFinal Results Update
10th May 201810:30 amRNSPlacing to Raise £1.47m and Live Market Bookbuild
3rd May 20187:30 amRNSSuspension Widecells Group
1st May 20187:02 amRNSAnnual Accounts and Fundraising Update
26th Mar 20187:00 amRNSLandmark deal to launch CellPlan insurance in Asia
19th Mar 20187:00 amRNSGranted Innovate UK KTP for Stem Cell Research
27th Feb 20187:00 amRNSLicence Award from the Human Tissue Authority
19th Feb 20187:00 amRNSBoard Changes and Launch of Wideacademy Platform
21st Dec 20177:00 amRNSCorporate Update
2nd Nov 20177:00 amRNSRevenue generation with White Apex agreement
12th Oct 20177:00 amRNSCellPlan expansion, e-commerce platform launch UK
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific
29th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSWideacademy Update, Presenting at Investor Event
15th Aug 20177:00 amRNSRaises £750,000 to support Company's divisions
31st Jul 20177:00 amRNSResearch Licence Granted from HTA
24th Jul 20177:00 amRNSNew product to target the dental market
21st Jul 20177:00 amRNSCellPlan launches E-Commerce Platform in the UK
12th Jul 20177:00 amRNSCorporate Charity Commitment
4th Jul 20177:00 amRNSAgreement to Roll Out CellPlan in Brazil

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.